Liraglutide Treatment in Obese Infertile PCOS Women
NCT06742710 on ClinicalTrials.gov · last registry update 2025-05-29
An unusually large phase 4: 890 participants, more than double the 75 typical for the stage. Due to report 30 May 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: Live birth rate associated with single cycle frozen embryo transfer. Sponsors move these dates routinely; any movement since this site started watching is listed below. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Peking University Third Hospital
- Sponsor type
- Other
- Enrollment
- 890
- Started
- 2025-05-22
- Primary completion
- 2029-05-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Live birth rate associated with single cycle frozen embryo transfer
Conditions studied
PCOS · Obesity · Infertility
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.